VivoSeq
Other

NF1

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

NF1 is an early-stage landscape with 0 programs across 1 company. The most active players are AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Not yet recruiting1 · 33%

Clinical Trials

Trial Activity

A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers
Completed·GGL Pharm Tech Corporation·Phase 1·NCT02072213·36 enrolled
Selumetinib Paediatric NF1 Japan Study
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT04495127·12 enrolled
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Not yet recruiting·—·Phase 1/2·NCT06735820·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)